eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple endocrine neoplasia type 1 |
| Comorbidity | C0024623|gastric cancer |
| Sentences | 9 |
| PubMedID- 23411963 | But there is no evidence that trastuzumab added to the other regimen improved survival in patients with advanced gastric cancer. |
| PubMedID- 21792201 | In conclusion, docetaxel–capecitabine is an active first-line regimen in patients with advanced gastric cancer, which can be given on an outpatient basis. |
| PubMedID- 24649156 | In conclusion, the pap score may be useful in selecting the best chemotherapeutic regimen in patients with non-resectable gastric cancer. |
| PubMedID- 23613400 | A multi-institutional evaluation of carboplatin plus docetaxel regimen in elderly patients with advanced gastric cancer. |
| PubMedID- 24728052 | The her2 inhibiting antibody trastuzumab successfully improves prognosis when added to the chemotherapy regimen in patients with her2-positive advanced gastric cancers [20]. |
| PubMedID- 25057084 | [effect of s-1 maintenance chemotherapy following dcf regimen in patients with advanced gastric cancer]. |
| PubMedID- 23748805 | One-day dcf regimen in patients with metastatic gastric cancer. |
| PubMedID- 21811088 | Conclusion: the combination of docetaxel, oxaliplatin and capecitabine in the described mode of administration represents a relatively active and well-tolerated regimen in patients with advanced gastric cancer and warrants further evaluation. |
| PubMedID- 23065042 | This study evaluates the efficacy and safety of a modified folfox regimen in elderly patients with metastatic gastric cancer and presenting associated disease(s). |
Page: 1